Elsevier

The Lancet Oncology

Volume 12, Issue 4, April 2011, Pages 319-321
The Lancet Oncology

Comment
MicroRNA therapeutics in preclinical cancer models

https://doi.org/10.1016/S1470-2045(11)70067-5Get rights and content

Section snippets

Glossary

Autochthonous
A tumour that is formed in the place where it is originally found
Antagomir
An oligonucleotide used to silence microRNA

References (10)

There are more references available in the full text version of this article.

Cited by (49)

  • Targeted delivery of nucleic acids using microfluidic systems

    2020, Biomedical Applications of Microfluidic Devices
  • An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy

    2020, Life Sciences
    Citation Excerpt :

    Excluding Leukemias in which the malignant cells are easily accessed [4], in solid cancers tissue sampling is achieved by means of biopsy and surgery. Since the procedures are often taken when cancer has considerably developed, such assessments have poor prognostic values [1], Hence, microRNAs closely associated with malignant phenotypes are invaluable diagnostic markers in the initial stages of cancer [1,3–5,29,37,39,40]. Cancer progression can be halted by inhibition of oncogenic microRNAs and/or slicing them with synthetic mRNA-pairing microRNAs, induction of tumor-suppressing microRNAs and reducing microRNA expression through epigenetic manipulations such as promoter methylation.

  • Animal Models to Study MicroRNA Function

    2017, Advances in Cancer Research
  • Impact of MicroRNAs in the Cellular Response to Hypoxia

    2017, International Review of Cell and Molecular Biology
    Citation Excerpt :

    In particular, a better knowledge of hypoxamiR function in disease conditions for which hypoxia plays a major deleterious role may offer new innovative therapeutic strategies. Indeed, the development of MiRNA-based therapeutics is currently the subject of intensive research efforts especially in lethal and/or chronic diseases (Broderick and Zamore, 2011; Kim et al., 2011b; Pottier et al., 2014; Rupaimoole et al., 2011). MiRNAs have many advantages as a therapeutic modality.

View all citing articles on Scopus
View full text